GANX
Gain Therapeutics Inc
1.80$
+3.2%
vs. previous close
Closing price · As of: Sep 17, 2026
Statements
Cash Flow
Gain Therapeutics Inc (GANX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -18 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| -0.7 | -1.9 | -3.2 | -12 | -15 | -19 | -19 | -18 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | |
| – | 0.0 | 0.1 | 0.8 | 1.5 | 3.3 | 2.4 | 1.8 | |
| 0.0 | -0.1 | 0.0 | 1.8 | 1.3 | – | – | – | |
| 0.3 | 0.3 | 0.2 | -0.3 | 1.5 | 0.4 | -1.1 | -1.0 | |
| 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | |
| 0.0 | 0.0 | 0.0 | -0.1 | -15 | 10 | 5.0 | – | |
| 1.0 | 0.7 | 0.7 | 0.0 | -0.1 | -0.1 | -0.1 | -0.1 | |
| 1.0 | 1.8 | 10 | 42 | -0.1 | 13 | 13 | 28 | |
| 0.2 | -0.1 | 7.2 | 29 | -30 | 4.5 | -1.4 | 10 | |
| -0.8 | -1.9 | -3.3 | -12 | -15 | -19 | -19 | -18 |
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.